Mesoblast (NASDAQ:MESO) Stock Rating Lowered by Jefferies Financial Group

Jefferies Financial Group downgraded shares of Mesoblast (NASDAQ:MESO) from a buy rating to a hold rating in a research report sent to investors on Monday, MarketBeat reports.

A number of other equities research analysts have also recently commented on MESO. Cantor Fitzgerald reiterated an “overweight” rating on shares of Mesoblast in a research note on Thursday, August 29th. Piper Sandler increased their price objective on shares of Mesoblast from $11.00 to $15.00 and gave the company an “overweight” rating in a research report on Thursday, December 19th. StockNews.com cut shares of Mesoblast from a “hold” rating to a “sell” rating in a research note on Wednesday, September 4th. Finally, Maxim Group upgraded shares of Mesoblast from a “hold” rating to a “buy” rating and set a $12.00 price target on the stock in a research note on Tuesday, September 24th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and three have issued a buy rating to the company. According to data from MarketBeat.com, Mesoblast presently has a consensus rating of “Hold” and a consensus target price of $13.50.

Mesoblast Trading Down 1.2 %

Shares of MESO opened at $17.02 on Monday. The company has a current ratio of 1.18, a quick ratio of 1.18 and a debt-to-equity ratio of 0.21. Mesoblast has a 12 month low of $1.61 and a 12 month high of $19.15. The stock has a fifty day moving average price of $10.77 and a 200-day moving average price of $8.44.

Hedge Funds Weigh In On Mesoblast

Several hedge funds and other institutional investors have recently bought and sold shares of the business. Signaturefd LLC lifted its stake in Mesoblast by 128.7% during the 3rd quarter. Signaturefd LLC now owns 5,506 shares of the company’s stock valued at $45,000 after acquiring an additional 3,099 shares during the period. Pine Valley Investments Ltd Liability Co purchased a new position in shares of Mesoblast during the second quarter worth $80,000. Perkins Coie Trust Co lifted its position in Mesoblast by 15.0% during the third quarter. Perkins Coie Trust Co now owns 11,500 shares of the company’s stock valued at $94,000 after purchasing an additional 1,500 shares during the period. Rathbones Group PLC purchased a new stake in Mesoblast in the second quarter valued at $95,000. Finally, XTX Topco Ltd acquired a new stake in Mesoblast during the 2nd quarter worth about $103,000. Institutional investors and hedge funds own 1.43% of the company’s stock.

About Mesoblast

Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.